Company news
Lisata Therapeutics, Inc. (NASDAQ:LSTA) news
Lisata Therapeutics, Inc. news releases on 6ix. Latest, Oct 5, 2026: Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed…
Press releases & updates
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
October 5, 2026
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
September 17, 2026
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
August 4, 2026
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
June 10, 2026
Kuva Intends to Commence Tender Offer for Lisata Therapeutics by May 29, 2026
May 4, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 6, 2026
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
January 27, 2026
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
January 21, 2026
LSTA Releases Valuations Report on Level 3 Loans
December 4, 2025
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
November 6, 2025
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
November 4, 2025
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
October 30, 2025
Lisata Therapeutics to Present at LD Micro Main Event XIX
October 13, 2025
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
October 8, 2025
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
September 29, 2025
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
LSTA Applauds Executive Order Increasing 401 (K) Access to Private Markets Investments
August 7, 2025
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
July 31, 2025
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
July 17, 2025
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
July 15, 2025
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
June 26, 2025
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
June 17, 2025
Lisata Therapeutics to Present at the 2025 BIO International Convention
June 11, 2025
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
May 1, 2025
Lisata Therapeutics Announces Research License with Catalent
April 15, 2025
Lisata Therapeutics to Present at the Investival Showcase USA
March 6, 2025
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
March 5, 2025
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
February 20, 2025